weight loss drugs other than glp 1 GLP-1 Medication Guide: Wegovy vs Ozempic vs Saxenda Half of GLP-1 users ditch

Other factors that may be associated with the impairment of renal function are GLP-1-induced natriuresis and reduction in renal perfusion [147, 148]

Association of glucagon-like peptide-1 receptor agonists with risk of cancers-evidence from a drug target mendelian randomization and clinical trials

We are now at an inflection point for The Broadening of GLP-1 use, which will extend beyond US-based early adopters to date, to larger numbers of patients globally, Morgan Stanley analysts wrote this year

Glucagon-like peptide-1 receptor agonists rescued diabetic vascular endothelial damage through suppression of aberrant STING signaling

Exenatide-induced eosinophilic sclerosing lipogranuloma at the injection site

This medications safety profile has not been studied in patients under the age of 18, pregnant and lactating people, or those with normal BMIs. At the time of publishing, the FDA has only approved three GLP-1 agonists for weight loss: Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)